Low incidence of genotypic and phenotypic resistance in paediatric HIV-infected patients on long-term first-line antiretroviral triple therapy

AIDS

Volumn 15, Issue 8, 2001, Pages 1077-1079

  Linde, Richard ^a   Funk, Markus B ^a   Schuster, Tobias ^a   Wintergerst, Uwe ^b   Notheis, Gundula ^b   Klingebiel, Thomas ^a   Kreuz, Wolfhart ^a  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ADOLESCENT; ARTICLE; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; FEMALE; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; INCIDENCE; LONG TERM EXPOSURE; MALE; PHENOTYPE; PRIORITY JOURNAL; STRAIN DIFFERENCE;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; INDINAVIR; INFANT; LAMIVUDINE; MALE; NELFINAVIR; PHENOTYPE; POINT MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; TIME; VIRAL LOAD; ZIDOVUDINE;

EID: 0035947414     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200105250-00025     Document Type: Article

References (12)

1. 1. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society - USA Panel. JAMA 1998, 280:78-86.
2. 2. Working Group on Antiretroviral Therapy and Medical Management of Infants, Children and Adolescents with HIV Infection. Antiretoviral therapy and medical management of pediatric HIV infection. Pediatrics 1998, 102 (Suppl.):1029.
3. 3. Wahn V, Bialek R, Boehier T, et al. Empfehlungen zur antiretroviralen Therapie bei HIV-infizierten Kindern. Monatsschr Kinder-heilkd 1998, 146:1081-1091.
4. 4. Gibb DM, for the PENTA 5 Executive and the PENTA Steering Committees. A randomised trial evaluating three NRTI regimens with or without nelfinavir in HIV-infected children: 48-week follow-up from the PENTA 5 trial. 5th International Congress on Drug Therapy in HIV Infection. Glasgow, October 2000 [Abstract PL6.8].
5. 5. Patick AK, Duran M, Cao Y, et al. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. Antimicrob Agents Chemother 1998, 42:2637-2644.
6. 6. Kaya St. Drug resistance in a trial of nucleoside analogue and protease inhibitor therapy in children (PENTA 5). 5th International Congress on Drug Therapy in HIV Infection. Glasgow, October 2000 [Abstract P354].
7. 7. Funk MB, Linde R, Wintergerst U, et al. Preliminary experiences with triple therapy including nelfinavir and two reverse transcriptase inhibitors in previously untreated HIV-infected children. AIDS 1999, 13:1653-1658.
8. 8. Watson DC, Farley JJ, Efficacy of and adherence to highly active antiretroviral therapy in children with human immunodeficiency virus type 1. Pediatr Infect Dis J 1999, 18:682-689.
9. 9. Haubrich RH, Little SJ, Currier JS, et al. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. AIDS 1999, 13:1099-1107.
10. 10. Kellam P, Larder BA. Recombinant virus assay: a rapid phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type I isolates. Antimicrob Agents Chemother 1994, 38:23-30.
11. 11. Schinazi RF, Larder BA, Mellors JW, Mutations in retroviral genes associated with drug resistance, Int Antiviral News 1997, 5:129-142.
12. 12. Markowitz M, Conant M, Hurley A, et al. A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection. J Infect Dis 1998, 177:1533-1540.